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REVIEW
Burden of allergic respiratory disease: a 
systematic review
A. Linneberg1,2,3* , K. Dam Petersen4, J. Hahn‑Pedersen5, E. Hammerby5, N. Serup‑Hansen5 and N. Boxall6
Abstract 
This meta‑analysis compared the health‑related quality of life (HRQL) of patients with allergic rhinitis (AR) and/or aller‑
gic asthma (AA) caused by perennial house dust mite (HDM) versus AR and/or AA caused by seasonal pollen allergy. 
Following a systematic search, the identified studies used the disease‑specific rhinitis quality of life questionnaire or 
generic instruments (SF‑36 and SF‑12). Summary estimates obtained by meta‑analysis showed that HRQL in patients 
with perennial HDM allergy was significantly worse than that of patients with seasonal pollen allergy, when measured 
by both disease‑specific and generic HRQL instruments, and was reflected by an impact on both physical and mental 
health. A systematic review of cost data on AR and AA in selected European countries demonstrated that the majority 
of the economic burden was indirectly caused by high levels of absenteeism and presenteeism; there was little or no 
evidence of increasing or decreasing cost trends. Increased awareness of the detrimental effects of AR and/or AA on 
patients’ HRQL and its considerable cost burden might encourage early diagnosis and treatment, in order to minimize 
the disease burden and ensure beneficial and cost‑effective outcomes.
Keywords: Allergic rhinitis, Allergic asthma, Economic burden, Meta‑analysis, Systematic review, Quality of life
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Background
In Europe, approximately 23  % of the population is 
affected by allergic rhinitis (AR) [1]. The most common 
symptoms are sneezing, itchy nose, rhinorrhea, and/
or nasal congestion [2], with many patients experienc-
ing symptoms of at least moderate severity; one study 
estimated that 93  % of patients with AR who consulted 
general practitioners had symptoms that were moder-
ate-to-severe [3]. Studies of patients consulting general 
practitioners for AR reported that 18–48  % had symp-
toms that were not controlled by pharmacotherapy [4, 
5]. Despite the bothersome nature of symptoms, AR is 
often trivialized by the patient; less than half (45 %) seek 
medical advice or treatment for their condition [4], which 
results in under-treatment and poor control of symp-
toms. A UK study found that only 18 % of patients with 
AR had consulted their doctor about the condition in the 
preceding 2 years [6]. In a sample of 230 French patients 
with typical symptoms of AR, 19 % had never consulted 
their doctor about the problem, despite 90  % reporting 
that their nasal symptoms affected their daily lives, over 
half complaining of sleepiness and headaches, and 8  % 
reporting that they had taken time off work because of 
their rhinitis [7]. Allergic rhinitis is frequently accom-
panied by allergic asthma (AA), the prevalence of which 
increases from less than 2 % in individuals without AR to 
10–40 % in those with AR; this combination of upper and 
lower respiratory symptoms increases the overall impact 
on the patient [8–10].
There is now considerable evidence that the symp-
toms of AR and AA negatively affect patients’ health-
related quality of life (HRQL) [11–20]. This is supported 
by evidence that successful treatment of symptoms with 
allergy immunotherapy (AIT) [21–23] or symptomatic 
treatments [24–31] improves the HRQL of patients with 
AR. These improvements generally mirror those of con-
ventional clinical outcome measures, such as symptom 
and medication scores, and lung function tests [32]. 
Although clinical measures provide information on the 
affected organ systems, they do not capture the patient’s 
overall perception of the disease burden caused by the 
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physical, emotional, and social impairments in everyday 
life [33]. The wider impact of AR on patients’ lives is now 
acknowledged in the allergic rhinitis and its impact on 
asthma (ARIA) guidelines, which recognize the impact 
of HRQL on AR, and classify its severity based both on 
symptoms and its effect on HRQL [32].
There is evidence that AR represents a considerable 
economic burden [34, 35], with annual costs in the US 
in 2003 estimated at $2–$5 billion USD [34]. Indirect 
costs resulting from symptoms causing under-perfor-
mance or loss of productivity in the workplace were 
particularly high [36–39]. Data published after the pre-
sent study was completed show that patients with mild 
AR have less impact on the health economy, with costs 
of around a quarter of those with moderate-to-severe 
disease [39].
To date, there has been no systematic review of 
HRQL data in patients with perennial or seasonal 
allergies. The objective of this systematic review and 
meta-analysis was, therefore, to compare HRQL in 
individuals with AR and/or AA with perennial house 
dust mite (HDM) or seasonal AR caused by exposure 
to pollen, or both. As HRQL instruments/question-
naires are included in many clinical studies as a matter 
of course, HRQL measurements enable comparisons 
with data from individual studies. In addition, data on 
the economic burden of AR and AA in selected Euro-
pean countries were systematically reviewed in order to 
compare direct and indirect costs in patients with per-
ennial HDM and seasonal AR.
Methods
Search and identification of studies
To identify published articles on HRQL in individuals 
with AR and/or AA, and the economic burden of AR 
and AA, the following online databases were searched: 
MEDLINE and MEDLINE In-Process (1946–31 January 
2014); EMBASE (1988–2014 week 04); EconLit (1886–
January 2014); The Cochrane Library (Cochrane Central 
Register of Controlled Trials and Cochrane Database of 
Systematic Reviews); Database of Abstracts of Reviews 
of Effects; National Institute For Health Research Health 
Technology Assessment Programme databases; Health 
Economics Evaluation Database; National Guidelines 
Clearing House; NHS Evidence; EUROScan; and Clini-
caltrials.gov.
The search strategies and keywords used are presented 
in the Additional file 1. The MEDLINE, EMBASE, Econ-
Lit, Cochrane Library, Database of Abstracts of Reviews 
of Effects, and NIH HTA databases were searched simul-
taneously using OVID. Unless otherwise stated, the 
search covered the period from 1 January 2000–31 Janu-
ary 2014 (date of publication).
Study selection
Articles considered for inclusion included randomized, 
controlled trials, observational and ecological studies, 
and health economic analyses with HRQL and/or cost as 
a primary or secondary outcome from one or more of the 
eight countries of interest: Denmark, France, Germany, 
Italy, the Netherlands, Spain, Sweden and the United 
Kingdom. Eligible studies enrolled adults or children 
diagnosed with (based on positive skin prick tests and/
or specific IgE results), and/or treated for, HDM (Der-
matophagoides pteronyssinus or Dermatophagoides fari-
nae) allergy; allergy to grass pollen (orchard, meadow, 
ryegrass, sweet vernal, and timothy grasses), Artemisia 
pollen, ragweed pollen, or birch pollen; or AA (as defined 
in the individual studies). Studies of AIT and sympto-
matic treatments were eligible for inclusion.
Titles and abstracts identified by the literature search 
were reviewed by NB; a second senior epidemiologist 
assessed 10  % of the titles and abstracts, and any disa-
greements were resolved through discussion. Full text 
versions of potentially eligible studies were obtained and 
reviewed. Additional relevant articles were identified 
from the bibliography of some articles, and a report from 
a clinical trial containing unpublished data was provided 
by the sponsor. Titles and abstracts of the 20 highest 
ranked Google Scholar search results were also reviewed 
and compared with the results of the database search to 
ensure that no articles had been missed.
Data extraction and meta‑analysis
As the aim of this study was to gather information on the 
HRQL of patients before any intervention, baseline meas-
urements of HRQL (prior to any intervention) in patients 
with AR and/or AA were extracted from the selected 
studies. Means and standard deviations (SD) were col-
lected, or where this was not possible, were imputed 
from available statistics, according to the methods 
described in [40]. Where data were presented as p < 0.05 
or p < 0.01, values used for imputations were p = 0.049 
and p =  0.009, respectively. Six studies presented data 
graphically, and values were obtained using a ruler.
Meta-analyses were performed in Microsoft Excel, and 
heterogeneity was assessed using Q-tables [41]. Differ-
ences between subgroups were assessed by ANOVA [42]. 
Due to the expected differences in study design, random 
effects models were used to estimate the overall meas-
ure of HRQL and the error of the estimate. Pooled mean 
estimates were presented with standard errors and 95 % 
Confidence Intervals (CI).
Where possible, HRQL data were grouped by aller-
gen (perennial or seasonal); if the allergen was not 
stated, data were included in a ‘Mixed’ group. Some 
older articles did not specify the sensitizing allergen but 
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categorized patients as suffering from seasonal AR (SAR) 
or perennial AR (PAR); in these cases PAR was grouped 
with HDM allergy, and SAR with pollen allergy.
Cost data
Cost data were divided into direct costs (including phy-
sician visit, medication costs, hospital stays, comorbidity 
medication costs, comorbidity physician visits, emer-
gency room visits, acute ward visits, and outpatient care) 
and indirect costs related to loss of productivity (includ-
ing absenteeism, presenteeism, production loss, inability 
to perform usual daily activities, restricted usual daily 
activities). All costs were converted to 2013 international 
dollars ($), and expressed as purchasing power parities 
(PPP).
Results
Search results and selected studies
The electronic search retrieved 2963 abstracts and titles; 
2905 were retained for screening, and 2502 of these did 
not meet the inclusion criteria. Full text copies of 544 
articles were screened and 50 were retained for data 
extraction. One additional reference was identified from 
the reference section of an article [43] and data were 
included from an unpublished study report provided by 
the sponsor [44]. Flow of articles through the selection 
process and reasons for rejection are shown in Fig.  1. 
Among the studies reporting HRQL data, 3 included 
patients with AA; two with PAR+AA, and one with 
SAR+AA.
Baseline HRQL measurements: RQLQ and mini‑RQLQ
The disease-specific rhinitis quality of life questionnaire 
(RQLQ) is a validated HRQL instrument for adults that 
measures functional impairments due to seasonal or per-
ennial rhinoconjunctivitis of allergic or non-allergic ori-
gin. It comprises seven domains scored on a 7-point scale 
(from 0 = not impaired at all, to 6 = severely impaired), 
with higher scores reflecting poorer HRQL [45, 46].
Seventeen studies reported data obtained using RQLQ 
or mini-RQLQ measured at ‘baseline’, ‘the season before’ 
or on ‘a day without symptoms’ [5, 24, 43, 47–60]. One 
study included patients with SAR/pollen allergy only 
(n  =  83) and SAR/pollen allergy with associated AA 
(n =  52) [49]. Two studies [59, 60] contained data that 
did not correspond to the recognized RQLQ scale and 
were excluded from the analysis.
Pooling all the data gave a moderate degree of hetero-
geneity (I2 =  62  %) with an estimated summary RQLQ 
of 2.61 ± 0.10 (95 % CI 2.43–2.80). Grouping studies by 
allergy phenotype [SAR/pollen only, PAR/HDM only, or 
SAR/pollen and/or PAR (‘Mixed’ group)] gave I2 values of 
63 % (moderate) for SAR/pollen, 33 % (low) for ‘Mixed’ 
group, and −17  % (none) for the PAR/HDM groups. 
Summary RQLQ estimates for the respective groups 
were 2.04 ± 0.18 (95 % CI 1.68–2.41) for the SAR/pollen 
patient group (673 patients in 10 groups from 5 studies); 
3.06 ± 0.16 (95 % CI 2.75–3.37) for the Mixed group; and 
2.73 ± 0.12 (95 % CI 2.49–2.98) for the PAR/HDM only 
group (1520 patients in 10 groups from 6 studies) Fig. 2.
Baseline HRQL measurements: SF‑36 and SF‑12
The 36-Item Short Form Health Survey (SF-36) is a vali-
dated, non-disease-specific indicator of overall health 
status. It comprises 36 items in eight domains that reflect 
physical and mental functioning, which are scored from 0 
to 100, with a lower score indicating poorer HRQL [61]. 
The SF-12 instrument is a short form of the SF-36 ques-
tionnaire, comprising 12 items.
Seven studies reported data using SF-36 or SF-12 [13, 
14, 49, 52, 62–64]. One study included patients with 
SAR/pollen allergy only (n = 83) and SAR/pollen allergy 
with associated AA (n = 52) [49], and one included PAR/
HDM patients with AR (n = 85), AR + AA (n = 62) or 
rhinitis, asthma and atopic eczema/dermatitis syndrome 
(n = 31) [63]. Data from one study [64] were insufficient 
to calculate SDs and this study was excluded from the 
analysis.
Data for the two main SF-36 composite domains were 
analyzed, to investigate whether the effects of allergic res-
piratory disease on physical and mental HRQL differed. 
Heterogeneity was high when all SF-36 physical compo-
nent score (PCS) data were pooled (I2 =  84  %). When 
data were grouped by phenotype, there was no hetero-
geneity for SAR/pollen (I2  =  13  %) or the PAR/HDM 
group, (I2 = −61 %), and heterogeneity was low for the 
Mixed group (I2 =  57 %). Summary estimates of HRQL 
using the SF-36 PCS for respective phenotypic groups 
were: SAR/pollen group 64.19 ± 7.89 (95 % CI 48.7–78.6; 
201 patients in 4 groups from 2 studies); PAR/HDM 
group 49.06 ± 1.26 (95 % CI 46.6–51.5; 2255 patients in 
6 groups from 2 studies); and ‘Mixed’ group 50.12 ± 0.52 
(95  % CI 49.1–51.1; 4899 patients in 7 groups from 3 
studies) Fig. 3.
Heterogeneity between SF-36 Mental Component 
Scores (MCS) was moderate/high when all studies were 
pooled (I2 = 73 %). When presented by phenotypic sub-
groups, there was no heterogeneity for the SAR/pollen 
group (I2 = −8 %), and heterogeneity was low both in the, 
‘Mixed’ (I2 = 46 %) and PAR/HDM (I2 = 32 %) groups. 
Summary estimates for the MCS were: SAR/pollen group 
50.38 ± 6.46 (95 % CI 37.7–63.0; 201 patients in 4 groups 
from 2 studies); PAR/HDM group 47.58  ±  1.28 (95  % 
CI 45.1–50.1; 2255 patients in 6 groups from 2 studies); 
and ‘Mixed’ group 44.62 ± 0.39 (95 % CI 43.9–45.4; 4899 
patients in 7 groups from 3 studies) Fig. 4.
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Comparison of RQLQ total scores between SAR/pollen 
and PAR/HDM phenotypes
ANOVA indicated that the RQLQ summary estimates 
of all three groups were different (F = 3.53; p = 0.024), 
but that the Mixed and PAR/HDM groups were not dif-
ferent (F  =  0.134; p  =  0.134). RQLQ summary scores 
for the SAR/pollen and PAR/HDM groups were differ-
ent (F = 35.9; p ≤ 0.001), with the overall HRQL of PAR/
HDM patients worse than that of SAR/pollen patients 
(2.73 ± 0.12 vs. 2.04 ± 0.18; p ≤ 0.001) Fig. 5a.
Comparison of SF‑36 physical and mental component 
scores between SAR/pollen and PAR/HDM phenotypes
SF-36 PCS summary estimates were different between 
the three groups (F = 5.75; p = 0.017), with no difference 
between the Mixed and PAR/HDM group (F  =  0.857; 
p  =  0.355). The SF-36 PCS summary of the PAR/
HDM and SAR/pollen groups was different (F =  9.867; 
p = 0.002), with lower HRQL in the patients with PAR/
HDM allergy vs. SAR/pollen allergy. Figure 5b shows that 
the SF-36 PCS of patients in the PAR/HDM group was 
significantly worse than that of those in the SAR/pollen 
group (49.06 ± 1.26 vs. 64.19 ± 7.89; p = 0.002).
SF-36 MCS summary scores for the three groups 
were also different (F  =  4.95; p  =  0.007), with differ-
ences between the Mixed and the PAR/HDM groups 
(F =  8.169; p =  0.004), but not between the SAR/pol-
len and PAR/HDM groups (F = 0.357; p = 0.550), indi-
cating that HRQL in both groups was equally affected 
(47.58 ± 1.28 vs. 50.38 ± 6.46, p = 0.550). Figure 5b.
Baseline RQLQ and SF‑36 domain scores
Eight studies [5, 47, 51–53, 55, 56, 58] reported RQLQ 
domain scores, or variants thereof. The ‘activities’ domain 
showed the highest heterogeneity (I2 = 76 %), with little 
or no heterogeneity (I2 =  9  %) in ‘non-hayfever symp-
toms’, or ‘emotional problems’ (I2 = 18 %), and medium 
heterogeneity (I2 = 31–35 %) in the remaining domains 
Search strategy 
2963 abstracts 
retrieved 
2905 abstracts for 
screening 
Excluded: 58 abstracts 
Duplicates (58)   
544 publications for 
full length screening 
Excluded: 2502 abstracts 
Population not of interest (508) 
Intervention not of interest (218) 
Comparator not of interest (225)* 
Study design not of interest (1459) 
Outcome not of interest (407) 
50 articles with data 
to include 
Excluded: 493 abstracts 
Population not of interest (139) 
QoL not cost data not available (344) 
Publication type not of interest (12) 
Fig. 1 Schematic diagram of the selection process. Asterisk comparator not of interest = environmental control mechanisms, such as mattress 
protector or humidifier
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(Additional file  1: Figure S1). ‘Practical problems’ and 
‘activities’ were the most affected domains, with the 
‘emotional’ domain being the least affected (Fig. 6a).
Four studies [13, 14, 62, 63] reported SF-36 data by 
domain. The ‘role-emotional’ domain showed the highest 
heterogeneity (I2 = 43 %), with little or no heterogeneity 
in ‘physical activity’, ‘bodily pain’, ‘general health percep-
tion’, ‘vitality’ or ‘mental health’. (I2 =  0  % for all; Addi-
tional file  1: Figure S2). ‘Vitality’ was the most affected 
domain, with ‘physical activity’ being the least affected 
domain Fig. 6b. There were insufficient data to compare 
domain scores by allergy phenotype.
Financial burden of AR and AA
Eleven studies were included in the analysis of direct and 
indirect costs; nine studies reported data for countries of 
interest [24, 62, 65–71] and two studies [72, 73] reported 
information for multiple countries using France and the 
United Kingdom as reference countries for calculat-
ing PPP costs (see Tables 1, 2). No studies that reported 
AR costs by severity were identified. One of the 17 
studies included in the cost analysis was a randomized, 
controlled trial [72], and may not reflect costs in a real 
clinical practice setting.
Direct comparison of total direct and indirect costs was 
complicated by differences in cost assessment in each 
study. Within countries, specific categories of costs (e.g. 
GP/specialist/visits, hospitalizations, medications) varied 
across studies, but we found very limited or no evidence 
for a trend of increasing or decreasing direct and indirect 
costs. The majority of the direct costs for AR were borne 
by the GP services; for patients with AR + AA, the AA 
Study name
Colas 2006
Colas 2006
DiRienzo 2006
DiRienzo 2006
Ariano 2006
Ariano 2006
LaForest 2005
LaForest 2005
Radcliffe 2003
Radcliffe 2003
Bousquet 2013
Bousquet 2013
Bousquet 2013
Bousquet 2013
Ciprandi 2010
Petersen 2008
Brinkhaus 2008
Brinkhaus 2008
Brinkhaus 2008
Ciprandi 2007
Riechelmann 2010
Riechelmann 2010
Holmberg 2009
Holmberg 2009
Ariano 2006
Bachert 2004
Bachert 2004
Anna 2002
Gerth van Wijk 2000
Gerth van Wijk 2000
0 1 2 3 4 5 6 
PAR (I2=-17%) Mixed (I2=33%) SAR (I2=63%) 
Fig. 2 Forest plot of overall RQLQ baseline scores by phenotype, from 30 groups in 15 studies. Higher scores indicate poorer HRQL
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part of the costs concerned medication and hospitaliza-
tion costs. Medication costs, excluding over-the-counter 
medications, remained low Table 1.
The majority of the cost burden was indirect (Tables 1, 
2) and caused by high absenteeism and presenteeism. 
Due to the lack of data, it was not possible to determine 
which had the higher cost; however, based on categories 
within each country, both were generally greater than the 
direct costs.
Discussion
Grouping studies by seasonal or perennial symptoms 
gave an acceptable level of heterogeneity (I2  ≤  63  %) 
that allowed summary estimates of HRQL from RQLQ 
and SF-36 instruments to be determined. Heterogene-
ity was generally higher for the SAR/pollen phenotype 
than for PAR/HDM, which could reflect the different 
types of baseline measurements in the selected studies, 
or the large heterogeneity of SAR. Patients with PAR/
HDM allergy had poorer HRQL than those with SAR/
pollen allergy when measured by RQLQ, SF-36 total 
score, and SF-36 PCS. The underlying reason for this 
difference is unclear, and could be due to differences in 
symptom frequency, duration, or severity. In Northern 
Europe, the pollen season is largely confined to the sum-
mer months, with the season for grass pollen, which is by 
far the most frequent cause of pollinosis, usually lasting 
from mid-May to July [74]; at the height of the pollen sea-
son, patients with SAR suffer symptoms approximately 
50  % of the time and report an impact on their HRQL 
[75]. It can be hypothesized that the year-round nature of 
symptoms might be responsible for the observed poorer 
HRQL in PAR/HDM allergy; however, published studies 
report varying results. Bousquet found that the severity 
of AR was more important in determining HRQL, sleep, 
daily activities, and work performance than symptom 
duration [3]. Similar findings were reported by Delgado 
and colleagues, who observed that HRQL was lower 
in Spanish patients with olive or grass pollen allergy vs. 
HDM allergy. This was attributed to the greater sever-
ity of symptoms caused by the explosive nature of olive 
pollination, resulting in sudden and elevated pollen con-
centrations, in contrast to the more constant concentra-
tions of perennial allergens that were more tolerable for 
PAR (I2=-61%) 
Study
LaForest 2005
LaForest 2005
Majani 2001
Majani 2001
Witt 2009
Witt 2009
Brinkhaus 2008
Brinkhaus 2008
Brinkhaus 2008
Leynaert 2000
Leynaert 2000
Terreehorst 2006
Terreehorst 2006
Terreehorst 2006
Terreehorst 2006
Terreehorst 2006
Majani 2001
0 10 20 30 40 50 60 70 80 90 100 
Mixed (I2=57%) SAR (I2=13%) 
Fig. 3 Forest plot of baseline SF‑36/SF‑12 physical component scores from 17 groups in six studies by phenotype. 95 % confidence intervals for the 
Mixed and PAR summary measures are hidden by the symbols. Lower scores indicate poorer HRQL
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patients [76]. Another study reported no significant dif-
ferences in baseline RQLQ scores between patients with 
HDM, grass pollen, and Parietaria pollen allergy [48].
Analysis of SF-36 component scores showed that men-
tal and physical component scores were affected in sea-
sonal and perennial allergy, with HDM/PAR having a 
greater impact on physical vs. mental component scores. 
This supports the findings of other studies that report 
significant emotional problems and poor mental wellbe-
ing in patients with AR, in addition to physical symptoms 
[13, 33, 77].
Meta-analyses were performed using HRQL measures 
from generic and disease-specific instruments. Generic 
questionnaires, like the SF-36, measure a wide range of 
physical, mental and psychosocial functions; they can 
be used in different health conditions and in the general 
population, and have the advantage of allowing compari-
sons of burden of illness across different disorders. Dis-
ease-specific instruments like the RQLQ more accurately 
reflect the patient’s inherent disease-associated prob-
lems, but scores cannot be directly compared with other 
populations. Both the generic and RQLQ instruments 
show improvements in HRQL in patients treated for 
AR; disease-specific questionnaires tend to show more 
important improvements, as they focus on the areas that 
are impacted by the disease [32]. Nowadays, HRQL ques-
tionnaires are used almost routinely in clinical studies of 
allergy treatments. Observed changes in HRQL generally 
reflect clinical outcomes; however, some studies report 
changes in HRQL that are not captured by symptom 
scores. Therefore, monitoring patients’ HRQL in clini-
cal practice has been suggested as a possible strategy to 
improve the management of AR [78].
Our analysis does not permit comparison of the HRQL 
of AR patients with that of the general population; how-
ever, a Spanish cross-sectional study that investigated the 
overall HRQL of patients with AR using SF-12 reported 
that HRQL was 25 % lower than in the general population 
[79]. Poor HRQL in patients with AR is also supported 
by evidence that successful treatment of AR symptoms 
with AIT [21–23] or symptomatic treatment [24–31] 
improves patient’s HRQL scores. A comparison of pub-
lished EQ-5D utility baseline scores indicated that peren-
nial allergy and/or AA (13 patients with AR and 12 with 
AR+AA), on a typical day with allergy symptoms, had a 
score of 0.60 [23], indicating comparable HRQL to dia-
betes (0.83) [80], cardiovascular disorders (0.73), muscu-
loskeletal disorders (0.63), and psychosomatic disorders 
(0.57), when measured with the same EQ-5D instrument 
[81]. Ranges of published EQ-5D scores for AR and/
Study
LaForest 2005
LaForest 2005
Majani 2001
Majani 2001
Witt 2009
Witt 2009
Brinkhaus 2008
Brinkhaus 2008
Brinkhaus 2008
Leynaert 2000
Leynaert 2000
Terreehorst 2006
Terreehorst 2006
Terreehorst 2006
Terreehorst 2006
Terreehorst 2006
Majani 2001
0 10 20 30 40 50 60 70 80 90 100 
PAR (I2=32%) Mixed (I2=46%) SAR (I2=-8%) 
Fig. 4 Forest plot of baseline SF‑36/SF‑12 mental component scores by phenotype, from 17 groups in six studies. 95 % confidence intervals for the 
Mixed and PAR summary measures are hidden by the symbols. Lower scores indicate poorer HRQL
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or AA and other diseases are summarized in Fig. 7, and 
indicate that the impact of AR and/or AA on generic 
HRQL on a day with allergen exposure is not trivial, with 
an effect that is comparable to chronic conditions, such 
as liver disease, epilepsy, migraine, and visual disorders 
[23, 82–86].
There were insufficient data in the present analysis 
to compare HRQL in patients with AR vs. those with 
both AR and AA. Delgado and colleagues reported that 
HRQL associated with AR was worse in patients diag-
nosed with both AR and asthma than in those with only 
AR [76]. Using the SF-36 instrument, Leynaert reported 
that patients with asthma experienced greater impair-
ments in physical functioning that those with AR alone, 
but asthma did not further impair mental wellbeing of 
patients with AR [13].
The cost analysis shows variations in direct and indi-
rect AR costs between countries, which may result 
from true differences in AR costs or from differences in 
the health systems, diagnostic behavior, or reporting 
between countries. Indirect costs make up the major-
ity of the cost burden of AR, in line with the outcomes 
of the most recent European [39] and US studies [34]. A 
few studies have reported higher direct vs. indirect costs 
[35, 87]; however, many studies estimate indirect costs by 
multiplying patients’ salaries by the amount of time they 
are absent from work due to AR. Health impairments 
associated with AR are often not severe enough to cause 
absence from work, although they can interfere with cog-
nitive functioning, resulting in fatigue and an impaired 
ability to learn, concentrate, and make decisions [88], 
all of which can affect performance in the workplace. In 
one study, more than a third of patients with AR (36 %) 
reported reduced workplace performance, or ‘presentee-
ism’, which was higher than among patients with asthma 
(19 %) [89]. In the US, where up to 60 million people are 
affected by AR [90], annual productivity loss associated 
with a diagnosis of AR was estimated at $601 million in 
1995. When the use of sedating allergy medications and 
workers’ self-assessments of their reduction work pro-
ductivity due to AR were taken into account, the esti-
mated annual at-work productivity losses increased to 
$2.4–$4.6 billion [37]. In 2006, the cost of lost productiv-
ity in the workplace due to AR was $593 per employee per 
year, and exceeded that of stress ($518), migraine ($277), 
depression ($273), and arthritis/rheumatism ($269) [36]. 
Comorbid AA resulted in higher costs than AR alone 
[91], or AR with non-allergic asthma [92], indicating its 
importance in driving costs. The cost of productivity loss 
is greater than the cost of treating AR symptoms; how-
ever, many cost analysis studies do not consider the cost 
to the patient of over-the-counter AR medications, which 
could lead to an underestimation of direct costs [34].
Some limitations of the study design should be 
acknowledged. Search terms were chosen from the 
RQLQ and SF-36 questionnaires, or were based on the 
suspected impact of AA and AR on patients’ HRQL. 
The articles identified by the search were mainly safety 
or efficacy studies that included HRQL as a secondary 
endpoint. Consequently, abstracts that did not include 
secondary outcomes would not be identified by the 
search. This could introduce a bias, such that only studies 
reporting a change in HRQL were identified. Inclusion 
of patients with comorbid AA in some groups could also 
affect HRQL scores, although we estimate any effect to be 
small. Moreover, the study only included HDM, and not 
pet allergens, as perennial allergens for perennial aller-
gic rhinitis/asthma. Many of the studies from which data 
are collated were randomized controlled interventional 
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studies, which may tend to include patients with more 
severe symptoms.
Conclusions
This review presents summary data on HRQL levels in 
patients with allergic respiratory disease that may be 
used for comparison with assessments from individual 
studies. HRQL in PAR/HDM patients was significantly 
worse than that of SAR/pollen patients, when meas-
ured by both disease-specific and generic HRQL instru-
ments, and was reflected by an impact on both physical 
and mental health. SAR/pollen and PAR/HDM affected 
MCS to a similar degree, despite a greater impact of 
PAR/HDM on PCS. A comparison of published EQ-5D 
utility index scores showed that the impact of PAR, 
with or without AA, on patients’ HRQL was compara-
ble to other chronic diseases. The economic burden of 
AR is considerable, with indirect costs due to absentee-
ism and presenteeism making up the majority of costs. 
Greater awareness of the detrimental effects of AR 
on HRQL and its cost burden might encourage early 
diagnosis and treatment in order to minimize the dis-
ease burden and ensure beneficial and cost-effective 
outcomes.
Table 1 Direct costs
DKK Danish Krone, DEM Deutsche Mark, Multiple (1) Belgium, France, Germany, Italy, Spain, Multiple (2) United Kingdom, Germany, the Netherlands, Denmark, Sweden, 
Spain and Austria
Country Ref. Age group Direct costs Values
Disease Allergen Definition Country cur‑
rency
Year of  
currency
PPP (2013 Int$)
Denmark [65] Adult AR SAR/grass GP visit/extra GP visit/acute 
ward visit/loratadine/budeso‑
nide/fluticasone/salbutamol
307.49 2005 (€) 47.19
[66] Adult AR Mixed Healthcare 1964.00 2002 (DKK) 300.96
France [67] Adult AR PAR/HDM Desloratidine/medication 
(comorbidity)/medication 
(additional PAR)/GP visit/
comorbidity GP visit
373.32 2007 (€) 492.39
[68] Adult AR SAR/grass Direct costs 694.95 2003 (€) 261.64
PAR/HDM Direct costs 183.57 2003 (€) 130.71
Children SAR/grass Direct costs 140.33 2003 (€) 200.01
PAR/HDM Direct costs 279.33 2003 (€) 398.12
Germany [62] Adult AR Mixed GP visit/medication (unspeci‑
fied)/hospitalization
771.12 2009 (€) 993.71
[65] Adult AR SAR/grass GP visit/Extra GP Visit/Acute 
ward visit/loratadine/budeso‑
nide/fluticasone/salbutamol
383.85 2005 (€) 493.88
[69] Adult AR SAR/grass Direct costs 356.37 1991 (DEM) 351.56
AR PAR/HDM Direct costs 517.94 1991 (DEM) 884.64
AR+AA Mixed Direct costs 544.02 1991 (DEM) 887.16
Italy [70] Adult AR+AA Mixed Medication (unspecified)/
outpatient care/emergency 
department/hospitalization
1589.30 2004 (€) 2568.52
[71] Children and 
adolescent
AR SAR/grass Direct costs 500.00 2003 (€) 826.75
PAR/HDM Direct costs 518.00 2003 (€) 856.51
Mixed Direct costs 506.00 2003 (€) 836.67
Multiple (1) [72] Adult AR PAR/HDM GP visit/medication (unspeci‑
fied)
100.44 2002 (€) 149.07
Multiple (2) [73] Adult AR+AA SAR/grass Acute ward visit/asthma 
medication/budesonide/
DESLORATIDINE/Extra GP or 
specialist visit/fluticasone/GP 
visit/medication (unspeci‑
fied)/salbutamol
289.88 2005 (£) 527.27
Sweden [65] Adult AR SAR/grass GP visit/extra GP visit/acute 
ward visit/loratadine/budeso‑
nide/fluticasone/salbutamol
595.80 2005 (€) 838.42
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Table 2 Indirect costs
DKK Danish Krone, Multiple (1) Belgium, France, Germany, Italy, Spain, Multiple (2) United Kingdom, Germany, the Netherlands, Denmark, Sweden, Spain and Austria
Country Ref. Age group Disease Indirect costs Values
Disease Allergen Definition Country  
currency
Year of  
currency
PPP (2013 Int$)
Denmark [65] Adult AR SAR/grass Absenteeism 667.36 2005 (€) 102.26
[66] Adult AR Mixed Patient/societal 30606.00 2002 (DKK) 4689.98
France [67] Adult AR PAR/HDM Absenteeism/presenteeism/
Wage per work day
1480.68 2007 (€) 1952.95
[68] Adult AR SAR/grass Indirect costs 210.86 2003 (€) 229.67
AR PAR/HDM Indirect costs 161.14 2003 (€) 300.52
Germany [62] Adult AR Mixed Indirect costs 765.84 2009 (€) 1073.38
[65] Adult AR SAR/grass Absenteeism 352.04 2005 (€) 523.04
Italy [71] Children and
adolescent
AR SAR/grass Indirect costs 2222.00 2003 (€) 3674.08
PAR/HDM Indirect costs 2057.00 2003 (€) 3401.25
Mixed Indirect costs 2166.00 2003 (€) 3581.48
Multiple (1) [72] Adult AR PAR/HDM Absenteeism/presenteeism/
Inability to perform usual daily 
activities/restriction over usual 
daily activities
4160.40 2002 (€) 6174.94
[24] Adult AR PAR/HDM Absenteeism/presenteeism 1826.88 2001 (€) 2711.49
Multiple (2) [73] Adult AR+AA SAR/grass Absenteeism/presenteeism/pro‑
duction loss
983.17 2005 (£) 1788.29
Sweden [65] Adult AR SAR/grass Absenteeism 384.62 2005 (€) 50.68
Netherlands [65] Adult AR SAR/grass Absenteeism 810.12 2005 (€) 1140.01
UK [65] Adult AR SAR/grass Absenteeism 408.41 2005 (€) 742.85
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Fig. 7 Range of EQ‑5D utility index scores for selected chronic conditions. Green and red circles represent the upper and lower values, respectively. 
Values were obtained from published studies in populations with cancer [82], psoriasis [82], cardiovascular diseases [82], visual disorders [82], type‑2 
diabetes mellitus [82], end stage renal disease [82], epilepsy [83], AR/HDM or AR and AA [23, 84], migraine [84] or chronic migraine [85], liver disease 
[82], and active psychoses [84, 86]. Lower EQ‑5D values indicate lower HRQL
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